Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion type Assertion NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_head.
- NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_provenance.
- NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion evidence source_evidence_literature NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_provenance.
- NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion SIO_000772 23635776 NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_provenance.
- NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion wasDerivedFrom befree-20140225 NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_provenance.
- NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion wasGeneratedBy ECO_0000203 NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_provenance.